| Randomised trial of ramipril in repaired tetralogy of Fallot and pulmonary regurgitation The APPROPRIATE study (Ace inhibitors for Potential PRevention Of the deleterious effects of Pulmonary Regurgitation In Adults with repaired TEtralogy of Fallot). | |
| | |
MedLine Citation:
|
PMID: 20970202 Owner: NLM Status: In-Data-Review |
Abstract/OtherAbstract:
|
BACKGROUND: Optimal treatment for stable repaired tetralogy of Fallot (rTOF) patients with pulmonary regurgitation (PR) and related right ventricular (RV) dilatation, including timing of valve implantation, remains uncertain. We sought to study tolerability of the angiotensin-converting-enzyme (ACE) inhibitor ramipril and its effects on cardiovascular function in these patients. METHODS: Clinically stable rTOF patients with moderate/severe PR were included. A double-blinded, placebo-controlled study of 6months of ramipril vs placebo was performed. All patients underwent cardiovascular magnetic resonance (CMR), echocardiography, neurohormonal analysis, and objective cardiopulmonary exercise testing at baseline and follow-up. PRIMARY ENDPOINT: The main aim was to detect changes in RV function (primary endpoint CMR-derived RV ejection fraction). RESULTS: Seventy-two patients were enrolled and 64 qualified for the final analysis. There was no difference in the primary endpoint RV ejection fraction. RV long-axis shortening significantly improved in the ramipril group compared to placebo (RV: 2.3±3.8 vs 0.02±2.7mm; P=0.017) as did LV long-axis shortening (1.9±4.5 vs -0.2±3.7mm respectively; P=0.030). No clear differences were detected between ramipril and placebo for other measures. In a subgroup of patients with restrictive RV physiology, ramipril resulted in decrease in LV end-systolic volume index and increase in LVEF (-2.4±5.0 vs 2.7±3.6mL/m(2); P=0.005, 2.5±5.0 vs -1.3±3.5%; P=0.03). Ramipril did not cause adverse events and was well tolerated. CONCLUSIONS: Ramipril is a well tolerated therapy, improves biventricular function in patients with rTOF and may have a particular role in patients with restrictive RV physiology. Larger, longer-term studies are needed to determine if ACE inhibitors can improve both ventricular remodelling and clinical outcomes. (ISRCTN: 97515585). |
| | |
Authors:
|
Sonya V Babu-Narayan; Anselm Uebing; Periklis A Davlouros; Michael Kemp; Simon Davidson; Konstantinos Dimopoulos; Stephanie Bayne; Dudley J Pennell; Derek G Gibson; Marcus Flather; Philip J Kilner; Wei Li; Michael A Gatzoulis |
Publication Detail:
|
Type: Journal Article Date: 2010-10-22 |
Journal Detail:
|
Title: International journal of cardiology Volume: 154 ISSN: 1874-1754 ISO Abbreviation: Int. J. Cardiol. Publication Date: 2012 Feb |
Date Detail:
|
Created Date: 2012-01-20 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 8200291 Medline TA: Int J Cardiol Country: Netherlands |
Other Details:
|
Languages: eng Pagination: 299-305 Citation Subset: IM |
Copyright Information:
|
Copyright © 2010. Published by Elsevier Ireland Ltd. |
Affiliation:
|
Royal Brompton and Harefield NHS Trust, London, UK; National Heart and Lung Institute, Imperial College London, UK. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: NYHA class I heart failure is not 'mild'.
Next Document: A familial case of malignant early repolarization.